Skip to main content
OpenTrials
Completed

NCT Number: NCT00977275

Treatment of T1N0 Invasive Breast Carcinoma by Local Excision Implant

The purpose of this study is to evaluate radiation therapy directed to a small region of the breast in women who were recently diagnosed with early stage invasive breast cancer.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1 / Phase 2

Primary location

Massachusetts General Hospital

Boston, Massachusetts, 02114, United States

About this study

  • When participants undergo surgery to remove the tumor (lumpectomy), it will be followed by the placement of small flexible tubes throughout the region surrounding the site of operation. These tubes will remain in place for 7-9 days following the surgery.
  • The first 2-3 days, the tubes will not contain radioactivity. This time is used to do all the calculations necessary for treatment and to check the findings in the breast tissue that was removed. After 2-3 days, the tubes will be filled with a radioactive wire which will remain in place for the next 5 days. During this period of time, participants will be required to remain within the hospital. At the end of these 5 days, the radioactive wires and tubes will be removed.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Low risk of multifocal disease within the breast whose tumor location is favorable for brachytherapy catheter placement
  • Diagnosis of invasive breast carcinoma (biopsy or fine needle aspiration cytology) and be clinical stage T1N0 (primary tumor < 2cm, clinically negative nodes)
  • Location of primary tumor is not immediately adjacent to the nipple of chest wall
  • No evidence of two or more separate tumors within the breast
  • All histologic types and pathologic grades of primary tumor
  • No extensive intraductal component (substantial intraductal carcinoma away from the primary tumor location)
  • No lymphatic or vascular invasion
  • Lymph node staging by sentinel node excision or axillary dissection confirms node negative status (If node positive, implant is used to deliver boost to tumor bed)
  • Assessment of final surgical margins should be predominantly negative, but a single small region of focal positivity is allowable as it is for whole breast radiation
  • 18 years of age or older

Exclusion criteria

  • Tumor is too close to the chest wall to allow placement of catheters
  • Contraindications to radiation therapy are present, including a history of scleroderma, systemic lupus or other active connective tissue disease, pregnancy, or prior chest wall radiation

Treatment and study plan

Interstitial Implant Brachytherapy

Radiation

Via tubes placed at the time of wide local excision delivered over 5 days

Primary outcomes

  1. To determine if interstitial implant brachytherapy to radical radiation doses is feasible following wide local excision of T1N0 breast carcinoma

    Time frame: 3 years

Sponsors and collaborators

Lead sponsor

Massachusetts General Hospital

Other

Registry information

Official study title

The Treatment of T1N0 Invasive Breast Carcinoma by Local Excision and Interstitial Implant

Important dates

Study start
1997
Primary completion
2006
Study completion
2013
First posted
Sep 15, 2009
Registry last updated
Apr 11, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.